Herman H.W. Silljé

The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF

Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Clonal Haematopoiesis of Indeterminate Potential: Associations with Heart Failure Incidence, Clinical Parameters and Biomarkers

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy

Novel heart failure biomarkers: why do we fail to exploit their potential?

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production

Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development

Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization

Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy

Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy

AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes

AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway

Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis